| Description | PR-104 sodium is a hypoxia-activated DNA cross-linking agent used in the research of tumor xenograft models. It functions as a nitrogen mustard pre-prodrug and efficiently transforms into the more lipophilic dinitrobenzamide mustards alcohol PR-104A. |
| In vitro | PR-104 (sodium) (80 μM; 1 hour; SiHa cells) shows greater suppression of radiation-induced DNA single-strand breaks under hypoxic than aerobic conditions. PR-104 (sodium) (100 μM; 1 hour; SiHa cells) results in phosphorylation of Ser139 of histone H2AX (gH2AX). PR-104 (sodium) (0.266 mmol/kg; 18 h; SiHa cells) shows activity against hypoxic cells after irradiation. PR-104 (sodium) varies in potency between cell lines, with the lowest IC 50 (0.51 μmol/L) in H460 cells and highest (7.3 μmol/L) in PC3 prostate cells[1]. |
| In vivo | PR-104 (sodium) (0.56 mmol/kg; i.v. or i.p.; 0~2 hours) makes the plasma area under the curve. PR-104 (sodium) (0.23 mmol/kg; i.p.; 100 days) shows antitumor activity[1]. Animal Model: CD-1nu/nu mice Dosage: 0.56 mmol/kg (Pharmacokinetics Analysis) Administration: I.v. or i.p. Result: The plasma area under the curve. Animal Model: CD1-Foxn1nu mice Dosage: 0.23 mmol/kg Administration: I.p. Result: Showed antitumor activity. |
| molecular weight | 602.26 |
| Molecular formula | C14H20BrN4NaO12PS |
| CAS | 851627-80-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Patterson AV, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res. 2007;13(13):3922-3932. |